Article
Psychiatry
Chih-Ken Chen, Shu-Yu Yang, Seon-Cheol Park, Ok-Jin Jang, Xiaomin Zhu, Yu-Tao Xiang, Wen-Chen Ouyang, Afzal Javed, M. Nasar Sayeed Khan, Sandeep Grover, Ajit Avasthi, Roy Abraham Kallivayalil, Kok Yoon Chee, Norliza Chemi, Takahiro A. Kato, Kohei Hayakawa, Pornjira Pariwatcharakul, Margarita Maramis, Lakmi Seneviratne, Kang Sim, Wai Kwong Tang, Tin Oo, Norman Sartorius, Chay-Hoon Tan, Mian-Yoon Chong, Yong Chon Park, Naotaka Shinfuku, Shih-Ku Lin
Summary: This study investigated the distribution of mood stabilizer prescriptions for different psychiatric diagnoses in 10 Asian countries and found that mood stabilizers are commonly prescribed for conditions other than bipolar disorder, with schizophrenia and other non-mood psychotic disorders being the most common diagnosis. Valproic acid was the most frequently used medication.
ASIAN JOURNAL OF PSYCHIATRY
(2023)
Article
Clinical Neurology
Balwinder K. Singh, Anastasia Yocum, Rebecca E. Strawbridge, Katherine E. Burdick, Caitlin T. Millett, Amy H. Peters, Sarah Sperry, Giovanna Fico, Eduard Vieta, Norma Verdolini, Ophelia Godin, Marion Leboyer, Etain F. Bruno, Ivy J. Tso, Brandon G. Coombes, Melvin A. McInnis, Andrew H. Nierenberg, Allan M. Young, Melanie Ashton, Michael J. Berk, Lana Williams, Kamyar N. Keramatian, Lakshmi J. Yatham, Bronwyn M. Overs, Janice Fullerton, Gloria B. Roberts, Philip A. Mitchell, Ole C. Andreassen, Ana P. Andreazza, Peter Zandi, Daniel M. Pham, Joanna A. Biernacka, Mark Frye, FACE BD Collaborators, Global Bipolar Cohort Collaborativ
Summary: This study investigated pharmacotherapeutic treatment patterns in multiple cohorts of individuals with bipolar disorder (BD) in North America, Europe, and Australia. Mood-stabilizing anticonvulsants, second-generation antipsychotics, and antidepressants were the most commonly prescribed medications. There were significant differences in prescription practices among different geographic regions.
Article
Psychiatry
Pao-Huan Chen, Shang-Ying Tsai, Po-Yu Chen, Chun-Hung Pan, Sheng-Siang Su, Chiao-Chicy Chen, Chian-Jue Kuo
Summary: This study evaluated the association between the use of mood stabilizers and the risks of mortality in people with bipolar disorder. The results showed that the use of mood stabilizers was significantly associated with decreased risks of all-cause mortality, suicide, and natural mortality, with lithium associated with the lowest risk.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Review
Clinical Neurology
Beatriz Corte-Real, Rodrigo Saraiva, Catarina Rodrigues Cordeiro, Benicio N. Frey, Flavio Kapczinski, Taiane de Azevedo Cardoso
Summary: The study aimed to investigate whether atypical antipsychotics (AA) can induce mania in mood disorders. A systematic review and meta-analysis showed that AA-induced mania is rare and the use of AA is more effective in preventing the development of mania compared to placebo.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Psychology, Developmental
Robert L. Findling, Xiaofeng Zhou, Prethibha George, Phillip B. Chappell
Summary: This study found that the diagnosis of DMDD has been rapidly adopted in clinical practice, but it is associated with increased prescriptions of antipsychotics and polypharmacy, higher rates of comorbidity, and inpatient hospitalization among youth compared with a diagnosis of BPD.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2022)
Review
Clinical Neurology
Aran Tajika, Hikaru Hori, Jun-ichi Iga, Yosuke Koshikawa, Haruhiko Ogata, Yusuke Ogawa, Koichiro Watanabe, Tadafumi Kato, Koji Matsuo, Masaki Kato
Summary: Existing meta-analytic evidence suggests that augmentation therapy is more effective than monotherapy in the treatment of bipolar mania. Significant improvement can be observed as early as the first week, and the effectiveness continues for up to 6 weeks. However, attention to side effects is necessary.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Clinical Neurology
Jonne Lintunen, Markku Lahteenvuo, Antti Tanskanen, Jari Tiihonen, Heidi Taipale
Summary: This study investigated the prevalence of primary non-adherence to medication and its associated factors in patients with bipolar disorder in Finland. The majority of patients did not adhere to their prescribed medications, with factors such as young age, recent diagnosis of bipolar disorder, multiple hospitalizations, and use of benzodiazepines or antidepressants being associated with an increased risk of non-adherence.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Clinical Neurology
Fabiano A. Gomes, Raphael O. Cerqueira, Yena Lee, Rodrigo B. Mansur, Flavio Kapczinski, Roger S. McIntyre, Lakshmi N. Yatham, Michael Berk, Roumen Milev, Elisa Brietzke
Summary: This study systematically reviewed 29 guidelines published by national and international organizations from 1994 to 2020, revealing that most guidelines make non-recommended treatment suggestions for patients with bipolar disorder. However, there is significant variation in how information regarding lack of efficacy data or potential harm is conveyed to the reader.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Biochemistry & Molecular Biology
Ritu Nayak, Idan Rosh, Irina Kustanovich, Shani Stern
Summary: Bipolar disorder and schizophrenia are psychiatric disorders with heterogeneous conditions and variable heredity. Mood stabilizers like lithium and valproic acid have shown effectiveness in treatment trials. Using induced pluripotent stem cells as disease models can help understand the molecular etiologies of these disorders and alleviate some disease phenotypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Clinical Neurology
Parya Valizadeh, Giulia Cattarinussi, Fabio Sambataro, Paolo Brambilla, Giuseppe Delvecchio
Summary: This review examines the impact of medication on neuroimaging findings in pediatric bipolar disorder (PBD). The results show that medication primarily affects the prefrontal cortex and amygdala, and has the potential to normalize brain structure and function in key mood-regulating regions.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Clinical Neurology
Ching-Hua Lin, Hung-Yu Chan, Cheng-Chung Chen, Frank Huang-Chih Chou
Summary: Prescribing patterns for patients with bipolar disorder discharged from two public psychiatric hospitals in Taiwan changed significantly over a 14-year period, with increased prescription rates of antipsychotics and antidepressants, and decreased rates of mood stabilizers. These changes were not in line with evidence-based treatment and guidelines, indicating a need for further exploration of long-term outcomes.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Pharmacology & Pharmacy
Mutahira M. Qureshi, Allan H. Young
Summary: Research has provided good quality evidence on the treatment and management of bipolar disorder in acute and sub-acute phases, but there is still a lack of high-quality research evidence on long-term treatment, particularly on discontinuing mood stabilizing pharmacological agents. Future research is needed to establish the best strategies for medication discontinuation in the long-term management of bipolar disorder.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2021)
Review
Neurosciences
Janusz K. Rybakowski
Summary: The narrative review focuses on mood stabilizers. It provides the author's definition of mood-stabilizing drugs and describes the two generations of drugs that meet this definition. The article presents the clinical experiences with first and second-generation mood stabilizers and discusses their use in preventing recurrences of bipolar mood disorder.
Article
Psychiatry
Juulia Poranen, Aura Koistinaho, Antti Tanskanen, Jari Tiihonen, Heidi Taipale, Markku Lahteenvuo
Summary: A study on the medication use patterns in patients newly diagnosed with bipolar disorder (BD) in Finland over the past 20 years showed that the use of antidepressants is too prevalent, the use of lithium is declining and needs to be increased, and long-acting injectable antipsychotics (LAI) are underutilized compared to their oral counterparts.
ACTA PSYCHIATRICA SCANDINAVICA
(2022)
Article
Psychiatry
Chu-Chun Lin, Ling-Ling Yeh, Yi-Ju Pan
Summary: The study found that mood stabilizers are associated with a decreased overall mortality in patients with bipolar disorder, while the use of antipsychotics appears to be associated with an increased mortality risk, with the risk increasing with dosage. Researchers suggest carefully considering potential adverse effects and benefits when prescribing psychotropic medications for long-term use in bipolar disorder patients.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Review
Clinical Neurology
Samantha E. Russell, Anna L. Wrobel, David Skvarc, Bianca E. Kavanagh, Melanie M. Ashton, Olivia M. Dean, Michael Berk, Alyna Turner
Summary: Comorbid PTSD may affect the pharmacologic treatment outcomes for adults with bipolar disorder. Further research is needed to inform pharmacotherapy selection and guidelines for individuals with comorbid bipolar disorder and PTSD.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Anna L. Wrobel, Sue M. Cotton, Anuradhi Jayasinghe, Claudia Diaz-Byrd, Anastasia K. Yocum, Alyna Turner, Olivia M. Dean, Samantha E. Russell, Elizabeth R. Duval, Tobin J. Ehrlich, David F. Marshall, Michael Berk, Melvin G. McInnis
Summary: This study compared the networks of depressive symptoms among individuals with bipolar disorder with and without a history of childhood trauma. It found that depressed mood consistently emerged as a central symptom regardless of childhood trauma history. Among individuals with a history of childhood trauma, feelings of worthlessness emerged as a key symptom in the network of self-reported depressive symptoms. These findings provide insights into the impact of childhood trauma on depressive symptoms in bipolar disorder.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Article
Substance Abuse
Gregory Carter, Matthew J. Spittal, Linda Glowacki, Dimitri Gerostamoulos, Paul Dietze, Barbara Sinclair, Shalini Arunogiri, Michael Berk, Dan I. Lubman, Victoria Manning, Peter Higgs, Brendan Quinn, Amanda Baker, Olivia M. Dean, Alyna Turner, Rebecca McKetin
Summary: The aim of this study was to estimate the negative predictive value (NPV) of self-reported non-use of methamphetamine compared with an oral fluid reference standard for treatment of methamphetamine dependence. The findings suggest that self-report of no recent methamphetamine use is sufficiently accurate to be clinically useful in treatment settings.
Review
Biochemistry & Molecular Biology
Bruna Panizzutti, David Skvarc, Sylvia Lin, Sarah Croce, Alcy Meehan, Chiara Cristina Bortolasci, Wolfgang Marx, Adam J. Walker, Kyoko Hasebe, Bianca E. Kavanagh, Margaret J. Morris, Mohammadreza Mohebbi, Alyna Turner, Laura Gray, Lesley Berk, Ken Walder, Michael Berk, Olivia M. Dean
Summary: Minocycline has been found to have anti-inflammatory, antioxidant, and anti-apoptotic properties, which has led to a renewed interest in using it as an adjunctive treatment for psychiatric and neurological conditions. A systematic review and meta-analysis of the available data from clinical trials using minocycline was conducted, showing limited and difficult to interpret results for most conditions, but suggesting an overall benefit for using minocycline as an adjunctive treatment for schizophrenia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Psychiatry
Michael Berk
Article
Pharmacology & Pharmacy
Ivana Bojanic, Ottar Bjerkeset, Lana J. Williams, Michael Berk, Johan Hakon Bjorngaard, Erik R. Sund, Hege Sletvold
Summary: This study examined the relationship between the use of cardiovascular drugs and metformin and the risk of initiating antidepressant use. The findings suggest that ARBs and CCBs as monotherapy may reduce the risk, while ASA or statins as polytherapy may also decrease the risk. However, the limitations in the study design may introduce bias.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2023)
Article
Psychiatry
Dhamidhu Eratne, Matthew Kang, Charles Malpas, Steve Simpson-Yap, Courtney Lewis, Christa Dang, Jasleen Grewal, Amy Coe, Hannah Dobson, Michael Keem, Wei-Hsuan Chiu, Tomas Kalincik, Suyi Ooi, David Darby, Amy Brodtmann, Oskar Hansson, Shorena Janelidze, Kaj Blennow, Henrik Zetterberg, Adam Walker, Olivia Dean, Michael Berk, Cassandra Wannan, Christos Pantelis, Samantha M. Loi, Mark Walterfang, Samuel F. Berkovic, Alexander F. Santillo, Dennis Velakoulis, MiND Study Grp
Summary: This study investigated the diagnostic utility of blood biomarkers of neuronal injury, specifically neurofilament light, in differentiating neurodegenerative disorders from primary psychiatric disorders (PPD). The results showed that neurofilament light could accurately distinguish behavioral variant frontotemporal dementia (bvFTD) from PPD. Large reference data sets and models were used to interpret individual levels, and slightly higher neurofilament light levels were found in bipolar affective disorder (BPAD) compared to controls and treatment-resistant schizophrenia (TRS).
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2023)
Article
Clinical Neurology
Balwinder K. Singh, Anastasia Yocum, Rebecca E. Strawbridge, Katherine E. Burdick, Caitlin T. Millett, Amy H. Peters, Sarah Sperry, Giovanna Fico, Eduard Vieta, Norma Verdolini, Ophelia Godin, Marion Leboyer, Etain F. Bruno, Ivy J. Tso, Brandon G. Coombes, Melvin A. McInnis, Andrew H. Nierenberg, Allan M. Young, Melanie Ashton, Michael J. Berk, Lana Williams, Kamyar N. Keramatian, Lakshmi J. Yatham, Bronwyn M. Overs, Janice Fullerton, Gloria B. Roberts, Philip A. Mitchell, Ole C. Andreassen, Ana P. Andreazza, Peter Zandi, Daniel M. Pham, Joanna A. Biernacka, Mark Frye, FACE BD Collaborators, Global Bipolar Cohort Collaborativ
Summary: This study investigated pharmacotherapeutic treatment patterns in multiple cohorts of individuals with bipolar disorder (BD) in North America, Europe, and Australia. Mood-stabilizing anticonvulsants, second-generation antipsychotics, and antidepressants were the most commonly prescribed medications. There were significant differences in prescription practices among different geographic regions.
Review
Psychiatry
Michael Berk, Ole Kohler-Forsberg, Megan Turner, Brenda W. J. H. Penninx, Anna Wrobel, Joseph Firth, Amy Loughman, Nicola J. Reavley, John J. Mcgrath, Natalie C. Momen, Oleguer Plana-Ripoll, Adrienne O'Neil, Dan Siskind, Lana J. Williams, Andre F. Carvalho, Lianne Schmaal, Adam J. Walker, Olivia Dean, Ken Walder, Lesley Berk, Seetal Dodd, Alison R. Yung, Wolfgang Marx
Summary: Populations with common physical diseases are more likely to have major depressive disorder (MDD), and people with MDD are at a greater risk for physical diseases. This comorbidity is associated with worse outcomes, reduced treatment adherence, increased mortality, and higher healthcare utilization and costs. Shared genetic and biological pathways, as well as social and lifestyle factors, contribute to the high prevalence of comorbidity. Pharmacotherapies and psychotherapies are effective treatments, and lifestyle interventions and collaborative care models show promise for improving management.
Article
Psychiatry
Roger S. Mcintyre, Mohammad Alsuwaidan, Bernhard T. Baune, Michael Berk, Koen Demyttenaere, Joseph F. Goldberg, Philip Gorwood, Roger Ho, Siegfried Kasper, Sidney H. Kennedy, Josefina Ly-Uson, Rodrigo B. Mansur, R. Hamish McAllister-Williams, James W. Murrough, Charles B. Nemeroff, Andrew A. Nierenberg, Joshua D. Rosenblat, Gerard Sanacora, Alan F. Schatzberg, Richard Shelton, Stephen M. Stahl, Madhukar H. Trivedi, Eduard Vieta, Maj Vinberg, Nolan Williams, Allan H. Young, Mario Maj
Summary: Treatment-resistant depression is common and has serious public health implications. The lack of a consensus definition hampers accurate estimates of its prevalence and efforts to identify effective interventions, leading to heterogeneity in treatment decision-making and potentially compromising quality of care.
Article
Medicine, General & Internal
Aswin Ratheesh, Dylan Hammond, Michael Watson, Jennifer Betts, Emma Siegel, Patrick Mcgorry, Michael Berk, Susan Cotton, Andrew Chanen, Barnaby Nelson, Andreas Bechdolf
Summary: The study found that patients meeting bipolar at-risk (BAR) criteria were more likely to transition to bipolar disorder (BD) over a decade after diagnosis compared to patients not meeting the criteria. This suggests that patients meeting BAR criteria may require longer-term monitoring and support.
Article
Nutrition & Dietetics
Julie A. Pasco, Michael Berk, Brenda Penninx, Natalie K. Hyde, Kara L. Holloway-Kew, Emma C. West, Mark A. Kotowicz, Kara B. Anderson, Adrienne O'Neil, Pamela G. Rufus-Membere, Lana J. Williams
Summary: This longitudinal study reports that women with both obesity and systemic inflammation are at increased risk of subsequent major depressive disorder (MDD). Future research should examine whether reducing the risk of depression in this metabolically unhealthy obesity type through lifestyle or medication interventions is possible.
FRONTIERS IN NUTRITION
(2023)
Review
Nutrition & Dietetics
Hajara Aslam, Mojtaba Lotfaliany, Daniel So, Kirsten Berding, Michael Berk, Tetyana Rocks, Meghan Hockey, Felice N. Jacka, Wolfgang Marx, John F. Cryan, Heidi M. Staudacher
Summary: This study conducted a systematic literature review and meta-analysis to explore the effects of dietary fibers on depressive and anxiety outcomes. The results showed a negative correlation between fiber intake and depressive and anxiety outcomes in observational studies. However, current randomized controlled trials did not support the use of fiber supplementation for improving depressive or anxiety outcomes. Further research, including clinical trials in specific populations and using a wider range of fiber types, is needed.
Article
Psychiatry
Anna Gimenez-Palomo, Mariona Guitart-Mampel, Ana Meseguer, Roger Borras, Francesc Josep Garcia-Garcia, Esther Tobias, Laura Valls, Xavier Alsina-Restoy, Gemma Roque, Ester Sanchez, Josep Roca, Gerard Anmella, Marc Valenti, Lorenzo Bracco, Helena Andreu, Sergi Salmeron, Lluc Colomer, Joaquim Radua, Norma Verdolini, Michael Berk, Eduard Vieta, Gloria Garrabou, Isabella Pacchiarotti
Summary: This study investigated mitochondrial respiration in patients with BD during mood episodes and found that there was a significant increase in maximal oxygen consumption capacity after clinical remission. This suggests that bioenergetic and mitochondrial dysregulation may be present in both manic and depressive phases of BD, and could potentially serve as biomarkers for illness activity and clinical response. Further research with larger samples is needed to confirm these findings.
ACTA PSYCHIATRICA SCANDINAVICA
(2023)
Article
Psychiatry
Alessandra Sarmiento, Olivia M. Dean, Bianca E. Kavanagh, Mohammadreza Mohebbi, Michael Berk, Seetal Dodd, Sue M. Cotton, Gin S. Malhi, Chee H. Ng, Alyna Turner
Summary: This study explores how personality disorder influences pharmacological treatment outcomes in individuals with bipolar disorder. The findings suggest that maladaptive personality traits can lead to poorer treatment outcomes and comorbid personality disorder may add additional burden to treatment. Understanding the impact of personality disorder on bipolar disorder is important for personalized treatment options.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)